Chittleborough T, Tapper R, Eglinton T, Frizelle Frank
Department of General Surgery, Christchurch Hospital, Private Bag 4710, Christchurch, 8140, New Zealand.
Department of General Surgery, University of Otago, Christchurch, New Zealand.
Tech Coloproctol. 2020 Feb;24(2):95-103. doi: 10.1007/s10151-019-02133-4. Epub 2019 Dec 13.
The term anal squamous intraepithelial lesion (ASIL) is used to describe premalignant change of anal squamous cells that precede the development of squamous cell carcinoma. Pathophysiology is driven by the human papilloma virus (HPV), and progression and regression of ASIL being well described, with 12% of high-grade lesions progressing to invasive cancer within 5 years. Vaccination against HPV is effective for primary prevention. Management consists of identification and treatment of high-grade lesions to prevent progression to squamous cell carcinoma. Management of established ASIL aims to avoid the progression to invasive cancer and maintain fecal continence. A combination of surveillance, excision, ablative, or topical therapies is used to achieve this. The aim of the present study was to review the contemporary evidence about ASIL and to suggest a management algorithm.
术语肛门鳞状上皮内病变(ASIL)用于描述在鳞状细胞癌发生之前肛门鳞状细胞的癌前变化。其病理生理学由人乳头瘤病毒(HPV)驱动,ASIL的进展和消退已有充分描述,12%的高级别病变在5年内进展为浸润性癌。HPV疫苗接种对一级预防有效。管理包括识别和治疗高级别病变以防止进展为鳞状细胞癌。已确诊的ASIL的管理目标是避免进展为浸润性癌并维持大便失禁。通过监测、切除、消融或局部治疗相结合来实现这一目标。本研究的目的是回顾关于ASIL的当代证据并提出一种管理算法。